NASDAQ:TTOO - Nasdaq - US89853L3024 - Common Stock
T2 BIOSYSTEMS INC
NASDAQ:TTOO (1/21/2025, 8:00:02 PM)
Premarket: 0.235 +0.01 (+2.22%)0.2299
-0.03 (-11.58%)
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -237.55% | ||
ROE | N/A | ||
Debt/Equity | N/A |
Achieved record fourth quarter and full-year 2024 sepsis product revenues...
Multiple instrument sale demonstrates growing market penetration of T2 Biosystems’ sepsis tests...
Milestone demonstrates the growing customer adoption of the Company’s proprietary technology...
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and...
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream...
Achieved 34% quarterly revenue growth compared to the prior year period...
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
T2 BIOSYSTEMS INC
101 Hartwell Ave
Lexington MASSACHUSETTS 02421 US
CEO: John Sperzel
Employees: 113
Company Website: https://www.t2biosystems.com/
Investor Relations: http://investors.t2biosystems.com/
Phone: 17814571200
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 16.06 | 305.03B | ||
AMGN | AMGEN INC | 14.3 | 147.72B | ||
GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
NTRA | NATERA INC | N/A | 22.11B | ||
BIIB | BIOGEN INC | 8.63 | 20.54B | ||
UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |